Study Conduct

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »

Medical Research Network expands with US office

Tuesday, October 25, 2011 01:21 PM

Medical Research Network (MRN) has opened a US office in Raleigh, North Carolina to better service clients in North America while at its UK headquarters in Milton Keynes, the company has completed a management restructure to allow the leadership team more time to focus on its continued expansion.

More... »

Middle East region poised for clinical trials growth

Monday, October 24, 2011 08:00 AM

With sponsors and CROs still on the hunt for emerging markets rife with treatment-naive patients and good infrastructure, interest in the Middle East is increasing.

More... »

Eagle Awards honor GSK, Medpace, Quorum IRB

Friday, October 21, 2011 11:14 AM

Sponsor GlaxoSmithKline, CRO Medpace and IRB Quorum Review all took home the coveted Eagle Award last Saturday, honored by investigative sites at the sixth annual Site Solutions Summit.

More... »

Cytonet’s SELICA III trial expands to Canada

Wednesday, October 19, 2011 10:58 AM

Canadian health authority, Health Canada, recently granted Cytonet approval to extend the SELICA III trial, which has been open in the United States since 2010, into Canada.

More... »

Almac, Greenphire collaborate in direct patient payment services

Thursday, October 6, 2011 11:39 AM

The Almac Group and Greenphire have reported that Almac’s Clinical Technologies business unit, the provider of IXRS (Interactive Voice and Web Response) services relating to patient and drug supply management, has formed an exclusive alliance with Greenphire to offer joint services relating to patient payment administration for clinical trials. This new service improves current methods of manual patient payment management and alleviates administrative burden on personnel in biopharmaceutical companies and contract research organizations, allowing them to focus on more study-specific responsibilities.

More... »

UK’s DNR to build clinical trials database for diabetes

Wednesday, September 28, 2011 12:31 PM

A new campaign launched by the UK’s Diabetes Research Network (DRN) aims to recruit up to 25,000 diabetes patients over an 18-month period to a ‘consent for approach’ database that should help to accelerate set-up times for clinical trials in the field, according to PharmaTimes.

More... »

FDA puts Immunomedics’ pancreatic cancer trial on hold

Friday, September 23, 2011 02:19 PM

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, been notified by the FDA that a partial clinical hold has been placed on the company’s phase Ib/II clinical trial of clivatuzumab tetraxetan in patients with advanced pancreatic cancer, due to the administration of an incorrect dose to a patient enrolled at one of its trial sites.

More... »

Cardio3 establishes US subsidiary

Friday, September 23, 2011 10:35 AM

Belgian cardiac cell therapies firm Cardio3 BioSciences established a U.S. subsidiary in Rochester, MN, to support its clinical and development activities and to bolster existing links with the Mayo Clinic and other U.S. collaborators, according to GEN News. Cardio3’s lead product, C3BS-CQR-1 is a stem cell-based cardiac lineage in clinical development for the treatment of heart failure. Phase III studies are projected to start in 2012.

More... »

Lilly steps up efforts to improve minority enrollment in clinical trials

Thursday, September 22, 2011 02:08 PM

Targeted trial sites, information on patient-assistance programs, on-site visits, culturally sensitive patient materials and amended protocol designs can all help to increase minority participation in clinical trials, a US study by Eli Lilly has indicated, according to PharmaTimes.

More... »